Table 1.
Basic characteristics of the study population.
| Characteristics | All (n = 94) | Discontinued group (n = 41) | Continued group (n = 53) | p-value |
|---|---|---|---|---|
| Age, years | 70.7 ± 9.9 | 72.3 ± 9.9 | 69.5 ± 9.9 | 0.1759 |
| < 75 years | 60 (63.9) | 25 (61.0) | 35 (66.0) | 0.6125 |
| ≥ 75 years | 34 (36.2) | 16 (39.0) | 18 (34.0) | |
| Sex | ||||
| Female | 27 (28.7) | 15 (36.6) | 12 (22.6) | 0.1384 |
| Male | 67 (71.3) | 26 (63.4) | 41 (77.4) | |
| BMI (kg/m2) | 23.1 ± 3.9 | 23.0 ± 3.1 | 23.1 ± 4.4 | 0.8988 |
| BSA (m2) | 1.6 ± 0.2 | 1.6 ± 0.2 | 1.6 ± 0.2 | 0.0852 |
| < 1.58 | 66 (70.2) | 22 (53.7) | 44 (83.0) | 0.0842 |
| ≥ 1.58 | 28 (29.8) | 19 (46.3) | 9 (17.0) | |
| Smoking history | ||||
| Never | 38 (40.4) | 17 (41.5) | 31 (58.5) | 0.1015 |
| Current/former | 56 (59.65) | 24 (58.54 | 22 (41.5) | |
| Fibrotic ILD | ||||
| IPF | 78 (83.0) | 33 (80.5) | 45 (84.9) | 0.5719 |
| SSC-ILD | 16 (17.0) | 8 (19.5) | 8 (15.1) | |
| HRCT pattern | ||||
| UIP | 83 (88.3) | 34 (82.9) | 49 (92.5) | 0.1542 |
| Others | 11 (11.7) | 7 (17.1) | 4 (7.5) | |
| GAP index | 0.0408 | |||
| Stage I (0–3) | 27 (28.7) | 12 (29.3) | 13 (24.5) | |
| Stage II (4–5) | 45 (47.9) | 15 (36.5) | 32 (60.4) | |
| Stage III (6–8) | 22 (23.4) | 14 (34.2) | 8 (15.1) | |
| Advanced ILDa | 22 (23.4) | 7 (17.1) | 15 (28.3) | 0.2023 |
| Chronic respiratory diseaseb | 39 (41.5) | 14 (34.2) | 25 (47.2) | 0.2038 |
| Inhaled medicine | 67 (71.3) | 29 (70.7) | 38 (71.7) | 0.3642 |
| LAMA alone | 6 (6.4) | 4 (9.8) | 2 (3.8) | |
| LABA + LAMA | 38 (40.4) | 14 (34.2) | 24 (45.3) | |
| LABA + ICS | 12 (12.8) | 4 (9.8) | 8 (15.1) | |
| LABA + LAMA + ICS | 11 (11.7) | 7 (17.1) | 4 (7.6) | |
| Oral corticosteroidc | 51 (54.3) | 19 (46.3) | 32 (60.4) | 0.1942 |
| Starting dose of nintedanib, n (%) | ||||
| 300 mg/day | 89 (94.7) | 39 (95.1) | 50 (94.3) | 0.8669 |
| < 300 mg/day | 5 (5.3) | 2 (4.9) | 3 (5.7) | |
| Acute exacerbation during follow-up, n (%) | 25 (26.6) | 14 (34.1) | 11 (20.8) | 0.0160 |
Values are displayed as number (%), mean ± standard deviation
BMI body mass index, BSA body surface area, DLco diffusion capacity of carbon monoxide, FVC forced vital capacity, GAP gender–age–physiology, ICS inhaled corticosteroid, ILD interstitial lung disease, LABA long-acting β2 agonist, LAMA long-acting muscarinic antagonist
aDLco pred ≤ 35% or FVC pred ≤ 50%
bChronic obstructive pulmonary disease or asthma
cBaseline using oral steroid before nintedanib management